Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type \% a; W+ |) [+ q6 q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% v# [5 M' `7 Z* j4 [ J Z+ Author Affiliations5 A) C6 H( o0 z q$ d
) P% C; f- p+ h7 a, J8 f6 b8 ^* i
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: U, J. u4 s& J0 E+ o2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' J* H6 G8 c4 T! r: d8 a _5 }3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' w3 N$ l" Q* J9 i s$ w$ _
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
9 B$ t4 K1 I5 r/ s1 X5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + [" i' ?* M7 S# v, o% B7 j
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 F, A. _# c" t/ `7 y" `# [7Kinki University School of Medicine, Osaka 589-8511, Japan
+ v f8 E6 N# m* M& O8 c) n. I8Izumi Municipal Hospital, Osaka 594-0071, Japan i/ R1 G/ d' u8 p1 L7 x; o7 G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ; d% \; j9 Q/ W) K
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp " e# H7 M" v: X; {- V; R/ W, M
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. $ ^2 H# A/ }9 s+ n4 K* |
6 A% U- E) w( T0 K6 o5 G& [ |